7681.T

The company maintains a strong liquidity position, with cash and equivalents amounting to ¥4,776,831,000, which is significantly higher than its total liabilities of ¥5,234,554,000. The current ratio of 2.23 indicates a solid ability to meet short-term obligations. However, the operating cash flow is negative at ¥-86,651,000, suggesting potential challenges in generating consistent cash from operations.

Profitability metrics show a return on equity of 2.71% and a return on assets of 1.41%, both of which are below the industry median for medical equipment and supplies. The company's operating income of ¥2,879,390,000 and net income of ¥152,779,000 indicate modest profitability, but the low returns suggest inefficiencies or competitive pressures in the market.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to regional economic or regulatory risks.

Looking ahead, the company's revenue is expected to remain stable, with no significant growth or decline projected in the next fiscal year. The capital expenditure of ¥-82,156,000 and free cash flow of ¥80,926,000 suggest a cautious approach to reinvestment and capital allocation.

The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's long-term debt is minimal at ¥7,190,000, and the debt-to-equity ratio is 0.0, suggesting a conservative capital structure.

Recent financial filings and transcripts do not highlight any major events or strategic shifts. The company's last actual EPS was 25.85 JPY, and its last actual revenue was ¥21,489,530,000, aligning with analyst estimates.